Viridian Therapeutics announced positive topline results from its Phase 3 THRIVE-2 trial of veligrotug for chronic thyroid eye disease, showing significant improvements in proptosis and diplopia compared to placebo, with 56% responder rates and a mean proptosis reduction of 2.34mm.